Earlier this year, Lonza entered into a strategic collaboration with Germany-based biotech Ethris to develop room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates designed for mucosal delivery. Room-temperature stability aims to address the supply chain challenges associated with mRNA vaccines, including a dependence on ultra-low-temperature storage and complex delivery systems. Source: The Medicine Maker 25/6/2025